Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Bristol Myers Squibb and Johnson & Johnson are both described as steady revenue growers, but with different business mixes. The article notes Bristol Myers Squibb’s accelerated U.S. FDA approval in August 2026 for Zenbexus, a combination therapy for adult multiple myeloma, and its selection of Houston for a new $2.3 billion multi-modal manufacturing campus aimed at boosting capacity for next-generation medicines. Johnson & Johnson, with a larger revenue base, completed a $1 billion cash acquisition of Firefly Bio in July 2026 to expand a targeted antibody-drug conjugate platform and received regulatory approval for IMAAVY for warm autoimmune hemolytic anemia. It also points to J&J medtech growth, including FDA market authorization for OTTAVA’s robotic surgical system in July, as a key area to watch.